COMPASS Pathways Plc - American Depository Shares (CMPS)

Competitors to COMPASS Pathways Plc - American Depository Shares (CMPS)

ATAI Life Sciences 

ATAI Life Sciences operates with a multi-asset psychedelics portfolio targeting mental health issues, including depression and anxiety, similar to COMPASS Pathways. Both companies conduct clinical trials to assess the effectiveness of psychedelic-based treatments, creating competitive tension in investor interest and market validity. However, ATAI has a broader strategy, pursuing various compounds and platforms, potentially placing them in a more advantageous position to diversify risk across their projects.

Field Trip Health Ltd.

Field Trip Health focuses on developing psychedelic-assisted therapies and operates wellness centers that provide ketamine treatments. COMPASS Pathways competes directly by also engaging in the clinical development of psilocybin therapies for depression. However, Field Trip has established physical presence and direct customer engagement through its clinic network, offering a tangible experience to patients that COMPASS lacks, providing Field Trip with an advantage in building brand loyalty and gathering patient feedback.

Mind Cure Health Inc.

Mind Cure Health focuses on creating and supporting the development of psychedelic products, with a strong emphasis on therapeutic applications much like COMPASS Pathways. Both companies are vying for the future of psychedelic-assisted therapy, with Mind Cure also placing a significant investment in a digital therapeutics platform to complement its treatment protocols, which could offer it an edge in the growing trend toward technology-enabled healthcare solutions. However, COMPASS’s advanced research and clinical trial maturity may still give it an edge in regulatory pathways.

MindMed 

MindMed focuses on developing psychedelic-inspired medicines for mental health disorders, similar to COMPASS Pathways, which is targeting treatment-resistant depression using psilocybin therapy. Both companies compete in the burgeoning psychedelics market, aiming to demonstrate clinical efficacy and secure regulatory approvals for therapy. While COMPASS has advanced its research significantly and garnered close ties with regulatory bodies, MindMed leverages a broader psychopharmaceutical development pipeline, which could provide a competitive edge in diversifying its portfolio beyond just psilocybin.

Psyched Wellness 

Psyched Wellness focuses on functional mushroom products and natural medicine for holistic well-being, which positions it in a broader wellness context compared to COMPASS Pathways' scientifically-oriented clinical trials to treat specific mental health conditions. The companies compete for consumer mindshare; COMPASS is more research-driven while Psyched Wellness appeals to a market interested in non-pharmaceutical approaches to mental health, offering a product line without the clinical rigor. This may offer Psyched Wellness a competitive edge in consumer markets despite the differing approaches.